Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag

Haematologica. 2019 Nov;104(11):e494-e496. doi: 10.3324/haematol.2019.216374. Epub 2019 Mar 19.

Authors

Bruno Fattizzo^{1

2}, Austin G Kulasekararaj¹, Anita Hill³, Nana Benson-Quarm¹, Morag Griffin³, Talha Munir³, Louise Arnold³, Kathryn Riley³, Robin Ireland¹, Hugues De Lavallade¹, Victoria Potter¹, Dario Consonni⁴, Peter Hillmen³, Ghulam J Mufti¹, Wilma Barcellini², Judith C W Marsh⁵

Affiliations

¹ Haematology, King's College Hospital, London, UK.
² Haematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
³ Haematology, St James's University Hospital, Leeds, UK.
⁴ Epidemiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
⁵ Haematology, King's College Hospital, London, UK judith.marsh@nhs.net.

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Anemia, Aplastic / diagnosis*
Anemia, Aplastic / drug therapy*
Anemia, Aplastic / etiology
Benzoates / administration & dosage
Benzoates / adverse effects
Benzoates / therapeutic use*
Biomarkers
Biopsy
Bone Marrow / pathology
Humans
Hydrazines / administration & dosage
Hydrazines / adverse effects
Hydrazines / therapeutic use*
Molecular Targeted Therapy
Prognosis
Pyrazoles / administration & dosage
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Treatment Outcome

Substances

Benzoates
Biomarkers
Hydrazines
Pyrazoles
eltrombopag